Measuring efficacy in cancer treatment can be challenging due to the heterogeneous nature of cancer. Different types of cancer and even subtypes within the same cancer can respond differently to the same treatment. Additionally, patient factors such as age, overall health, and genetic profile can influence efficacy. The design of clinical trials also plays a crucial role, as variations in study design, patient selection, and endpoint definitions can lead to different efficacy outcomes.
